Injection devices

Chronicle

2024: Global Injection Devices Market Reaches $4.31 Billion for the Year

At the end of 2024, the global market for injection devices amounted to $4.31 billion. About 40% of this amount fell on the North American region. Industry trends are addressed in the Fortune Business Insights survey published in early April 2025.

The study takes into account devices for self-injection - these are medical tools that allow patients to administer their own drugs without the need for outside assistance. Such products include automatic injectors, pen syringes, needle-free injectors, and wearable injectors. Conditions such as diabetes, anaphylaxis, rheumatoid arthritis and multiple sclerosis require frequent administration of drugs. Injection devices offer a convenient and effective solution for patients, allowing them to perform procedures at home or away from healthcare facilities. This eliminates the need for frequent visits to the hospital, which significantly increases the overall quality of life.

One of the key drivers of the industry in question, the authors of the study name technological advances in drug delivery. Developers are constantly improving the design of automatic injectors, which makes them more convenient for everyday use - especially for patients with limited skills or mobility.

An important role in expanding the market is played by the increasing prevalence of chronic diseases, including diabetes. As the population ages, health problems become more common, driving demand for effective and affordable injection devices. Against this background, regulators are taking measures to simplify the process of certification of medical devices. At the same time, manufacturers invest heavily in research and development aimed at improving the design and functionality of injectors. The pandemic has also had a stimulating effect on the industry. COVID-19

But there are also deterrents. One is the limited availability of modern drug delivery devices in low- and middle-income countries. Some self-injection solutions can be difficult to use for certain categories of patients, especially older adults. Plus, there are safety issues related to the misuse of injectors.

In 2024, the largest share of revenue was provided by pen syringes - 67.6%. The dominance of this segment is explained by factors such as ease of use, convenience and demand of devices for the therapy of various conditions, including diabetes and autoimmune diseases. Significant growth rates are observed in the automatic injectors sector. Geographically, North America is in the lead, where revenue was recorded at $1.75 billion in 2024. This is followed by Europe, while the Asia-Pacific region shows the fastest growth. Major players in the global market include:

• SHL Medical AG;
• BD;
• Crossject;
• PharmaJet;
• Ypsomed AG;
• Owen Mumford Limited;
• Recipharm AB;
• Gerresheimer AG;
• Halozyme.

In 2025, sales of injection devices worldwide are expected to rise to $4.88 billion. Fortune Business Insights analysts believe that in the future, the CAGR in the market under consideration will be 13.3%. As a result, by 2032, costs on a global scale could increase to $11.71 billion.^[1]

Notes